We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Nominations now open for PVRI Achievement Awards 2025
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. The PVRI Lifetime Achievement Award 2025 and the PVRI Achievement Awards 2025 will be presented at PVRI 2025 Rio. Nominate by 25 November 2024.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
The PVRI 2025 Annual Congress will be hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe will converge in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD. Register your place!
Webinar presentations: Identification of arterial and venous morphologic markers in pulmonary arterial hypertension using CT imaging; The keto diet as treatment for pulmonary hypertension associated with obesity; Endothelial transdifferential from exacerbated inflammatory signaling in BMP9 in lung endothelium; The role of pericytes in the pathophysiology of pulmonary arterial hypertension
Webinar presentations: Cellular mechosignaling in pulmonary arterial hypertension; Sex differences in pulmonary arterial hypertension randomized clinical trials; Precapillary pulmonary hypertension and death from COVID-19; Estradiol and estrogen receptor protection of right ventricular function – role of apelin; Prostacyclin reverses right ventricular hypertrophy and dysfunction in severe PAH; Pulmonary vascular complications of heart failure with preserved ejection fraction
The objective of this analysis was to compare clinician-based and formally calculated risk assessments by REVEAL Lite 2 and COMPERA 2.0 and to characterize parenteral prostacyclin utilization within 90 days of baseline in high-risk patients. A multisite, double-blind, retrospective chart review of patients with pulmonary arterial hypertension (PAH) was conducted with an index period of January 2014–March 2017.
Therapeutic exercise has not been widely adopted in pediatric pulmonary hypertension (PH), despite adult data supporting its safety and efficacy. While physical limitations may prevent children with PH from participating in physical activity, other barriers to and facilitators of physical activity are unknown.
Although surgical and interventional therapy has emerged as the primary treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), there remains a subset of patients who need medication therapy. This study aimed to evaluate the efficacy and safety outcomes of prostacyclin pathway vasodilators, providing further insight for clinical decision-making.
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. They celebrate notable achievements made by special individuals across the world. The PVRI Lifetime Achievement Award 2025 and the PVRI Achievement Awards 2025 will be presented at PVRI 2025 Rio.
On 27 September 2024, phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS) closed. The survey was first launched in October 2023 to help clinicians better understand the impacts of PH on patients.
This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research.
The PVRI launched the Pulmonary Hypertension Global Patient Survey (PH GPS) in October 2023 to help clinicians better understand the impacts of PH on patients. The first global survey of its kind was aimed at those living with PH and their carers.